Funds › Vivo Capital, LLC
Vivo Capital, LLC
13F for Q3 2026, filed Nov 13, 2026. 50 positions worth $908.7M.Managers with more than $100 million in US-listed stocks list their holdings each quarter, within 45 days of quarter end. Long positions only: no short sales or cash.
Latest report
Q3 2026
filed Nov 13, 2026
Reported value
$908.7M
−$186.4M (17.0%) vs Q2 2026
Positions
50
47 in Q2 2026
Top 10 share
51.3%
of reported value
CheckedEach line's price per share is checked against other managers' reports of the same stock. Unit mix-ups are corrected. Reports no fix can rescue are left out.
Clean
prices match other managers' reports
Ask your AI about this
Connect Claude, ChatGPT, Gemini or Grok (Microsoft 365 Copilot coming soon) to 13F.ai and ask in plain English. Copy a question to get started:
Using 13F.ai, what are the biggest new, added, trimmed and exited positions of Vivo Capital, LLC in the latest 13F quarter?
Using 13F.ai, how has Vivo Capital, LLC's portfolio concentration changed over the last four quarters?
Using 13F.ai, which of Vivo Capital, LLC's top holdings have also been bought by insiders recently?
Connect your AI · Plans and the 7-day free trial (card required)
Holdings, Q3 2026
Largest first. Common shares only.
| # | The fund's own figures at the end of the quarter. A report can be up to 45 days old when it is filed. Options and bonds are not counted here. | Filing | ||||
|---|---|---|---|---|---|---|
| 1 | PRAX Praxis Precision Medicines, Inc. | 271,116 | $79.0M | 8.7% | Unchanged | 13F ↗ |
| 2 | TRVI Trevi Therapeutics, Inc. | 4.23M | $60.6M | 6.7% | -17.0% | 13F ↗ |
| 3 | ERAS Erasca, Inc. | 4.02M | $58.9M | 6.5% | -2.6% | 13F ↗ |
| 4 | AVBP ArriVent BioPharma, Inc. | 1.79M | $54.1M | 6.0% | +6.2% | 13F ↗ |
| 5 | ABVX Abivax SA · ADR | 414,899 | $41.1M | 4.5% | Unchanged | 13F ↗ |
| 6 | ENTX Entera Bio Ltd. | 12.25M | $35.7M | 3.9% | New | 13F ↗ |
| 7 | ACRS Aclaris Therapeutics, Inc. | 6.69M | $35.2M | 3.9% | Unchanged | 13F ↗ |
| 8 | ANRO Alto Neuroscience, Inc. | 1.36M | $34.7M | 3.8% | +12.5% | 13F ↗ |
| 9 | TNGX Tango Therapeutics, Inc. | 1.38M | $34.4M | 3.8% | Unchanged | 13F ↗ |
| 10 | CRVS Corvus Pharmaceuticals, Inc. | 2.81M | $32.3M | 3.6% | Unchanged | 13F ↗ |
| 11 | LBRX LB Pharmaceuticals Inc | 800,000 | $30.7M | 3.4% | Unchanged | 13F ↗ |
| 12 | KRSA Korsana Biosciences, Inc. | 877,020 | $28.1M | 3.1% | New | 13F ↗ |
| 13 | BLSM BlossomHill Therapeutics, Inc. | 1.49M | $27.8M | 3.1% | New | 13F ↗ |
| 14 | FTH Faeth Therapeutics, Inc. | 844,576 | $25.1M | 2.8% | +17.0% | 13F ↗ |
| 15 | CAMP CAMP4 Therapeutics Corporation | 5.58M | $22.6M | 2.5% | +31.5% | 13F ↗ |
| 16 | ACHV Achieve Life Sciences, Inc. | 2.75M | $22.3M | 2.4% | Unchanged | 13F ↗ |
| 17 | SABS SAB Biotherapeutics, Inc. | 6.92M | $21.9M | 2.4% | -5.3% | 13F ↗ |
| 18 | DBVT DBV Technologies S.A. · ADR | 1.84M | $21.7M | 2.4% | Unchanged | 13F ↗ |
| 19 | DRUG Bright Minds Biosciences Inc. | 417,879 | $20.8M | 2.3% | -25.0% | 13F ↗ |
| 20 | DSGN Design Therapeutics, Inc. | 1.61M | $20.3M | 2.2% | Unchanged | 13F ↗ |
| 21 | ANTX AN2 Therapeutics, Inc. | 3.15M | $16.8M | 1.8% | Unchanged | 13F ↗ |
| 22 | MLTX MoonLake Immunotherapeutics | 1.40M | $16.4M | 1.8% | Unchanged | 13F ↗ |
| 23 | NERV Minerva Neurosciences, Inc | 4.32M | $14.5M | 1.6% | Unchanged | 13F ↗ |
| 24 | ODTX Odyssey Therapeutics, Inc. | 575,000 | $12.8M | 1.4% | Unchanged | 13F ↗ |
| 25 | ORIC Oric Pharmaceuticals, Inc. | 924,392 | $12.5M | 1.4% | -50.0% | 13F ↗ |
| 26 | EPRX Eupraxia Pharmaceuticals Inc. · Com 298736 Al 3 Euronet Worldwide Inc Note 0.750% 3/1 | 1.35M | $12.3M | 1.4% | Unchanged | 13F ↗ |
| 27 | VOR Vor Biopharma Inc. | 550,358 | $10.5M | 1.2% | New | 13F ↗ |
| 28 | EDIT Editas Medicine, Inc. | 3.56M | $9.1M | 1.0% | Unchanged | 13F ↗ |
| 29 | SRZN Surrozen, Inc. | 260,000 | $8.4M | 0.9% | Unchanged | 13F ↗ |
| 30 | DYN Dyne Therapeutics, Inc. | 514,402 | $8.3M | 0.9% | -67.0% | 13F ↗ |
| 31 | AURA Aura Biosciences, Inc. | 1.17M | $7.3M | 0.8% | Unchanged | 13F ↗ |
| 32 | CUE Cue Biopharma, Inc. | 280,057 | $7.2M | 0.8% | New | 13F ↗ |
| 33 | MNPR Monopar Therapeutics Inc. | 90,500 | $7.2M | 0.8% | Unchanged | 13F ↗ |
| 34 | MSLE Satellos Bioscience Inc. | 813,666 | $6.9M | 0.8% | Unchanged | 13F ↗ |
| 35 | OLMA Olema Oncology, Inc. | 671,843 | $5.8M | 0.6% | Unchanged | 13F ↗ |
| 36 | PEPG PepGen Inc. | 2.33M | $5.6M | 0.6% | Unchanged | 13F ↗ |
| 37 | OKUR OnKure Therapeutics, Inc. | 1.93M | $5.3M | 0.6% | Unchanged | 13F ↗ |
| 38 | ATTO Attovia Therapeutics, Inc. | 300,000 | $5.1M | 0.6% | New | 13F ↗ |
| 39 | ADRX ADARx Pharmaceuticals, Inc. | 255,158 | $5.1M | 0.6% | New | 13F ↗ |
| 40 | TENX Tenax Therapeutics, Inc. | 2.50M | $4.7M | 0.5% | Unchanged | 13F ↗ |
| 41 | VALN Valneva SE | 763,199 | $4.7M | 0.5% | Unchanged | 13F ↗ |
| 42 | AVTX Avalo Therapeutics, Inc. | 275,000 | $4.2M | 0.5% | Unchanged | 13F ↗ |
| 43 | CMPX Compass Therapeutics, Inc. | 3.42M | $3.6M | 0.4% | -55.9% | 13F ↗ |
| 44 | SERA Sera Prognostics, Inc. | 1.65M | $3.4M | 0.4% | Unchanged | 13F ↗ |
| 45 | TIL Instil Bio, Inc. | 292,743 | $2.1M | 0.2% | Unchanged | 13F ↗ |
| 46 | INM InMed Pharmaceuticals Inc. | 824,874 | $1.1M | 0.1% | +3.3% | 13F ↗ |
| 47 | BOLT Bolt Biotherapeutics, Inc. | 72,414 | $266.5K | <0.1% | Unchanged | 13F ↗ |
| 48 | KTTA Pasithea Therapeutics Corp. | 372,796 | $183.8K | <0.1% | -19.9% | 13F ↗ |
| 49 | DTIL Precision BioSciences, Inc. | 4,675 | $29.3K | <0.1% | Unchanged | 13F ↗ |
| 50 | JSPR Jasper Therapeutics, Inc. | 5,364 | $3,693 | <0.1% | New | 13F ↗ |
Changes since Q2 2026
8 new, 5 added to, 8 trimmed, 5 exited, 29 unchanged. By estimated dollars.
New positions (8)
| ENTX Entera Bio Ltd. | 12.25M | New | $35.7M |
| KRSA Korsana Biosciences, Inc. | 877,020 | New | $28.1M |
| BLSM BlossomHill Therapeutics, Inc. | 1.49M | New | $27.8M |
| VOR Vor Biopharma Inc. | 550,358 | New | $10.5M |
| CUE Cue Biopharma, Inc. | 280,057 | New | $7.2M |
| ATTO Attovia Therapeutics, Inc. | 300,000 | New | $5.1M |
| ADRX ADARx Pharmaceuticals, Inc. | 255,158 | New | $5.1M |
| JSPR Jasper Therapeutics, Inc. | 5,364 | New | $3,693 |
Added to (5)
Trimmed (8)
| DYN Dyne Therapeutics, Inc. | 514,402 | -67.0% | -$16.8M |
| ORIC Oric Pharmaceuticals, Inc. | 924,392 | -50.0% | -$12.5M |
| TRVI Trevi Therapeutics, Inc. | 4.23M | -17.0% | -$12.4M |
| DRUG Bright Minds Biosciences Inc. | 417,879 | -25.0% | -$6.9M |
| CMPX Compass Therapeutics, Inc. | 3.42M | -55.9% | -$4.5M |
| ERAS Erasca, Inc. | 4.02M | -2.6% | -$1.6M |
| SABS SAB Biotherapeutics, Inc. | 6.92M | -5.3% | -$1.2M |
| KTTA Pasithea Therapeutics Corp. | 372,796 | -19.9% | -$45.7K |
The 10 largest of each, by estimated dollars: shares changed times the later report's price. Index tracking, splits and mergers move positions too.
Compare two quarters
Pick any two quarters: what is new, added to, trimmed or exited. Premium plan.
Any two quarters side by side. Part of Premium.
Reported value by quarter
Value and number of positions at the end of each quarter.
Loading…
Largest positions in earlier quarters
Pick a quarter to see what the fund's biggest positions were then.
Loading…
Ten largest positions
By value, Q3 2026.
Filings
| Filing | ||||||
|---|---|---|---|---|---|---|
| Q3 2026 | Nov 13, 2026 | 13F-HR | 50 | $908.7M | Current | SEC ↗ |
| Q2 2026 | Aug 14, 2026 | 13F-HR | 47 | $1.1B | Current | SEC ↗ |
| Q1 2026 | May 20, 2026 | 13F-HR/A (restatement) | 46 | $1.2B | Current | SEC ↗ |
| Q1 2026 | May 15, 2026 | 13F-HR | 45 | $1.2B | Replaced | SEC ↗ |
| Q4 2025 | Feb 13, 2026 | 13F-HR | 47 | $1.5B | Current | SEC ↗ |
| Q3 2025 | Nov 14, 2025 | 13F-HR | 47 | $1.2B | Current | SEC ↗ |
| Q2 2025 | Aug 14, 2025 | 13F-HR | 42 | $977.1M | Current | SEC ↗ |
| Q1 2025 | May 12, 2025 | 13F-HR | 40 | $755.1M | Current | SEC ↗ |
Most recent first, up to 80. An amendment can replace a report or add holdings to it. All 13F filings
Information, not investment advice. Values are the fund's own figures at quarter end; a report can be up to 45 days old when filed. Disclaimer